GlassScriptPhysician profile
Nguyen-Steve D Vu
NPI 1427133347
$32,633.63
in general payments reported to CMS, 2019-2025
37 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,246 · 2020: $8,771 · 2021: $12K · 2022: $6,235 · 2023: $404 · 2024: $1,592 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,089 · Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,089.38 |
| Food and Beverage | $1,021.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22,951.58 | 2019-2024 | Arexvy, Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $1,729.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,242.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,234.69 | 2019-2025 | Fasenra, Tezspire |
| Intuitive Surgical, INC. | $1,089.38 | 2024 | |
| Sunovion Pharmaceuticals INC. | $472.20 | 2019-2021 | |
| Genzyme Corporation | $440.26 | 2019-2023 | |
| Mylan Specialty L.P. | $384.47 | 2019-2022 | |
| Genentech USA, INC. | $314.99 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $275.29 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $258.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $238.65 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $202.12 | 2019-2022 | |
| Insmed, INC. | $198.33 | 2019-2022 | |
| Harmony Biosciences LLC | $186.75 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $162.50 | 2019-2022 | |
| Philips North America LLC | $161.79 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $131.67 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $123.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.48 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $95.19 | 2019-2022 | |
| United Therapeutics Corporation | $64.47 | 2020-2021 | |
| Gilead Sciences, INC. | $63.03 | 2021-2022 | |
| Electromed, INC. | $63.02 | 2021-2022 | |
| Csl Behring | $56.40 | 2023 | Kcentra |
| Merck Sharp & Dohme LLC | $55.32 | 2019-2022 | |
| Covis Pharma Gmbh | $54.11 | 2022 | |
| Advanced Respiratory, INC | $49.12 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $48.79 | 2019-2021 | |
| Allergan, INC. | $29.61 | 2019 | |
| Mallinckrodt Enterprises LLC | $29.51 | 2019 | |
| Baxter Healthcare | $26.65 | 2022 | |
| Inogen, INC. | $22.87 | 2021 | |
| Shionogi INC | $21.69 | 2022 | |
| Shire North American Group INC | $19.96 | 2019 | |
| Pfizer INC. | $18.16 | 2024 | |
| Phadia US INC. | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nguyen-Steve Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.